Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You could be right
Yields dropping now.
It seems, more pain ahead. Treasuries Yields keep climbing today.
Unemployment rate in the main Parameter.
History never lie but meanwhile US Economy in it's best Strength Since 1969.
I have mentioned several red flags recently. Hope a few have listened
Thank you. Nice Board
No difference than other Biotech companies
https://www.proactiveinvestors.com/companies/news/206514/histogenics-aytu-bioscience-and-kenpharm-shares-tumble-on-share-offerings-206514.html
But this Company has 2 BlockBuster FDA approved drugs which the last just entered the market so there is no doubt about revenues surges upcoming earnings and beyond as well a big Cash Burn Cut, beside strong cash on hand now for at least 2 years. Someone might buy them up in 2019 ,make sense.
Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism
Pot Stocks: I'm actually focusing 3 stocks, GWPH with highest Market cap, then INSY and ZYNE. the last one has a strong buy recommendation by 4 Analysts. My fund go to 1/4, 1/4, 1/2
A good website to check analysts coverage
https://www.barchart.com/stocks/quotes/ZYNE
ZYNE Have you noticed Q4 Catalysts ?
https://t.co/B61h4QPLfI
#CBD
#FDA has granted Orphan Drug designation to Zynerba for the use of CBD as treatment of patients with FXS.
A strong buy by 4 Analysts ($21/sh) P.T
Yes
How many investors Do you guys know that plop down $5-$6m without DD or Potential especially when DATA date just on the Corner. Just saying
I'm actually focusing 3 stocks mentioned here . GWPH with highest Market cap, then INSY and ZYNE. the last one has a strong buy recommendation by 4 Analysts. My fund go to 1/4, 1/4, 1/2
A good website to check analysts coverage
https://www.barchart.com/stocks/quotes/ZYNE
Agree. Marijuana to be legal in Canada starting October 17.
2 Marijuana Biotechs to Watch
https://investorplace.com/2018/10/2-biotech-marijuana-stocks-to-watch/
interesting read. this month should great. need to pick 1 or 2 pot stocks w/a decent Market cap and solid balance sheet
Interesting Coverage: 2 Marijuana Biotechs to Watch https://investorplace.com/2018/10/2-biotech-marijuana-stocks-to-watch/
GWPH 2 Marijuana Biotechs to Watch https://investorplace.com/2018/10/2-biotech-marijuana-stocks-to-watch/
2 Marijuana Biotechs to Watch https://investorplace.com/2018/10/2-biotech-marijuana-stocks-to-watch/
ORPN $1.8 +34% mentioned it around $1.2 recently. pops again ( 3 times in one week but ended almost flat). Hard to guess what's going on. Company need cash but could also close a deal. A lotto.
IZEA +70%
IZEA I knew. All-Time Record Quarterly Bookings of $9.5 Million for Third Quarter 2018
DTEA what a day. numbers never lie. AYTU 1. Aytu BioScience granted U.S. patent for method of determing fertility potential
Read more at:
https://thefly.com/landingPageNews.php?id=2798690
2. A Possible New Alternative for Testosterone Supplementation/Replacement That Does NOT Hurt Male Fertility https://www.linkedin.com/pulse/possible-new-alternative-testosterone-does-hurt-male-seaman-m-d-
3. SEC Filing Shows Revenue Surge At Aytu Bioscience
"the current market cap of just $4.97 million as of September 28th may be ridiculously low".."In that case, a valuation of somewhere between $300-$500 million would be reasonable".
https://seekingalpha.com/instablog/49294679-soulstring-report/5218605-sec-filing-shows-revenue-surge-aytu-bioscience
4. big drop in cash burn rate and bigger cut also in 2019.
1. Aytu BioScience granted U.S. patent for method of determing fertility potential
Read more at:
https://thefly.com/landingPageNews.php?id=2798690
2. A Possible New Alternative for Testosterone Supplementation/Replacement That Does NOT Hurt Male Fertility https://www.linkedin.com/pulse/possible-new-alternative-testosterone-does-hurt-male-seaman-m-d-
3. SEC Filing Shows Revenue Surge At Aytu Bioscience https://seekingalpha.com/instablog/49294679-soulstring-report/5218605-sec-filing-shows-revenue-surge-aytu-bioscience
big drop in cash burn. and more than 50% in early 2019.
$$$$$
DTEA as i said, at least $3.5/sh ( above $4 as im writing). That's why you do DD
Agree. A debt-free too.
YTEN news. https://globenewswire.com/news-release/2018/10/02/1588493/0/en/Yield10-Bioscience-Obtains-Nonregulated-Status-for-its-Novel-CRISPR-Cas9-Triple-Gene-Edited-Camelina-Plant-Lines-to-Boost-Seed-Oil-Content.html
Trading around net assets which is way cheap compare the sector. A debt-free
DTEA took some profits, kept the rest. NBEV be careful. Too risky at current price. Market cap around $450m. net lose increased 10 times. almost zero cash, that's why company filed Form 424B5 ( sale of up to $50m shares). Could keep going but could also could crash.. trade smart
DTEA $3.5 +37%
2.96, +16% 300k a.h volume As mentioned before, fair value ( Equity, net assets) above $3.5/sh. Decision will be made by strong insiders+ inst. ( 86% ownership) not by CEO.
DTEA +11% After hours . w/ such a strong ownership of more than 86% by both insiders + inst., be sure they choose the best deal for them ( and shareholders ).check my DD, load, seat back, relax. a great reward here.
SEC Filing Shows Revenue Surge At Aytu Bioscience https://seekingalpha.com/instablog/49294679-soulstring-report/5218605-sec-filing-shows-revenue-surge-aytu-bioscience
DTEA is my largest position a/o today. fair value a/o today, at least $3.5/sh (Net assets),has $40m in Cash. 86% Ownership and 480 employees. with CBD in, probably +$20/sh (not yet but high possibility imo, Canada just became the second country in the world to legalize marijuana nationwide. Legal sales are set to begin October 17 and company confirmed marijuana producers are knocking on the door, no decision yet ). they have no competition in the tea market in Canada.
Most Cannabis stocks trading several times it's Equity, a few have Negative Equity and a few trading 100 to 1000 times. a strong buy to me, no doubt.
DTEA vs NBEV
DTEA $90m net assets, $39m Cash, market cap $65m.
NBEV $56m net assets, $213k cash, market cap $360m.
NBEV too risky at this point. almost zero cash and dilution is coming (more 50m shares thru offering).
DTEA a good strategy By CEO. that's how you can increase Bid offers. there is a good reason why many are knocking on the door. they will raise the "price" until somebody will
Make an offer he can't refuse. several solid reasons for that.Total ownership ( insiders+ Inst.) above 85%, Stock is higly undervalued, Net Assets $90m. Market cap is under $70m, not for long.
more to come. that's for sure.
$4 break
AYTU when you do DD you know why its a gold mine.
TSLA SEC charges Tesla, Elon Musk with fraud https://www.cnbc.com/2018/09/27/tesla-falls-4percent-on-report-elon-musk-sued-by-sec.html
I suspected it is inevitable.
I know MTH4, still holding, not my largest position a/o today.
very promising Breakthrough, thanks for sharing.